HCA Healthcare, Inc.

(New York Stock Exchange)
Back to all articles
Neutral +10

Barclays Issues Pessimistic Forecast for HCA Healthcare (NYSE:HCA ...

AI-generated analysis

πŸ“‰ Barclays lowered HCA's price objective from $427.00 to $402.00 while maintaining an 'equal weight' rating.

πŸ’° The company reported Q1 revenue of $19.11 billion, beating analyst estimates of $19.09 billion by a small margin.

πŸ“Š HCA missed quarterly EPS expectations with $7.15 actual versus a consensus of $7.19.

πŸ₯ Revenue grew 4.3% year-over-year, reflecting continued organic expansion and acquisitions in the healthcare sector.

πŸ“ˆ Sei Investments Co. increased its stake by 56.3% to own shares valued at roughly $52.3 million.

πŸ” Jump Financial LLC initiated a new position worth approximately $2.07 million during the second quarter.

πŸ›οΈ NewEdge Advisors LLC raised its holdings by 11.9%, now owning 3,859 shares valued at $1.334 million.

πŸ“… HCA has set FY 2026 guidance between $29.10 and $31.50 EPS against a consensus of $29.74.

βš–οΈ The stock holds an average analyst rating of 'Moderate Buy' with a consensus price target of $486.14.

πŸ“‰ Barclays' downgrade contrasts with Raymond James Financial's higher $528.00 target price for the stock.

Bullish Signals
  • Revenue of $19.11 billion exceeded analyst estimates of $19.09 billion, demonstrating top-line resilience.
  • Year-over-year revenue growth of 4.3% indicates successful expansion through organic growth and acquisitions.
  • Sei Investments Co. significantly increased its stake by 56.3%, signaling strong institutional confidence.
  • Jump Financial LLC initiated a new position valued at over $2 million, adding to bullish institutional activity.
  • NewEdge Advisors LLC lifted its position by 11.9%, further validating the stock's appeal to active managers.
Risk Factors
  • Barclays lowered its price objective from $427.00 to $402.00, reflecting a pessimistic near-term outlook.
  • The company missed quarterly EPS estimates by $0.04, reporting $7.15 versus the consensus of $7.19.
  • Return on equity is negative at 295.93%, indicating potential leverage or capital structure concerns.
  • Cantor Fitzgerald and Robert W. Baird have also recently reduced their price objectives for HCA.
Full Analysis
Barclays has lowered its price objective for HCA Healthcare (NYSE:HCA) from $427.00 to $402.00, citing a pessimistic outlook in a report issued on Thursday. The brokerage maintains an 'equal weight' rating, which implies a potential upside of 8.18% from the stock's previous close. This move adds to a mixed landscape of analyst sentiment, where other firms like Raymond James Financial hold a higher $528.00 target, while Robert W. Baird and Cantor Fitzgerald have recently reduced their own price objectives. The company reported quarterly earnings on April 24th with EPS of $7.15, slightly missing the consensus estimate of $7.19 by $0.04. Revenue reached $19.11 billion, beating estimates at $19.09 billion, driven by a 4.3% year-over-year increase. Despite the revenue beat, HCA reported a net margin of 8.89% and a negative return on equity of 295.93%. Analysts have set FY 2026 guidance between $29.10 and $31.50 EPS, while the consensus forecast stands at $29.74. Institutional ownership remains significant at 62.73%, with several major funds adjusting their stakes recently. Sei Investments Co. notably boosted its position by 56.3% in the second quarter to own shares valued at approximately $52.3 million. Other active investors include Jump Financial LLC, which established a new stake worth over $2 million, and NewEdge Advisors LLC, which lifted its holdings by 11.9%. The stock currently carries an average rating of 'Moderate Buy' with a consensus price target of $486.14.